Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.4.2.5 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.160.33NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.168NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
S.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.465NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.52NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.221.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.33.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.39NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
AY.71 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23154.2US
B.1.218NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.34.1.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.258.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.355NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.57NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.428NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.215NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.11 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AH.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.640.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.462NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.223NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.82NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.252NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.289NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
B.1.1.365NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.1.4.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.519NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EE.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DN.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.55NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.627NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.52NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.6.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1.1.29NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DJ.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAPNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.631NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.514NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CF.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBF.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FW.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.47.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23154.8US
BQ.1.1.58NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.4.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.87NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used